InhaltsangabeSection I: The New Helicobacters.- 1 What are the new helicobacters?.- 2 Helicobacter hepaticus and Helicobacter bilis: proinflammatory modulators of enterohepatic disease.- 3 Epidemiology and postulated pathogenesis of liver and biliary tract pathogenic Helicobacter species.- 4 Evidence implicating Helicobacter spp. in the pathogenesis of inflammatory bowel disease.- Section II: Strain Differences of Helicobacter pylori.- 5 The hierarchy of markers of virulence and disease causation - useful or disappointing?.- 6 SHP-2 tyrosine phosphatase and the Helicobacter pylori virulence factor CagA.- 7 What is the exact role of Lewis antigens and autoantibodies in Helicobacter pylori-related disease?.- 8 Putative role of Helicobacter antigen in functional dyspepsia: a conceptual model.- 9 Acid adaptation of Helicobacter pylori.- 10 Co-migration of Helicobacter pylori and humans: the evolving story.- Section III: Helicobacter pylori and Gastritis - The Ongoing Saga.- 11 Progress in our understanding of H. pylori infection and gastritis.- 12 The role of pepsinogen assays as surrogate markers of gastritis dynamics in population studies.- 13 Multifocal Atrophic Gastritis (MAG) does not exist: new finding based on sectioning the entire stomach.- 14 Multifocal Atrophic Gastritis (MAG) is real, and important.- 15 Are there reliable non-invasive approaches to assessing gastritis for epidemiologic studies?.- 16 Animal models of gastritis: Helicobacter pylori and high-salt diet in the gerbil.- Section IV: Helicobacter pylori and Gastric Malignancy.- 17 The evolving epidemiology of Helicobacter pylori infection and gastric cancer.- 18 Virulence of Helicobacter pylori infection and gastric cancer: lessons from mouse models.- 19 The role of bacterial overgrowth in the stomach as an additional risk factor for gastritis.- 20 Role of ascorbate in gastric juice and the impact of Helicobacter pylori infection.- 21 Mechanisms of injury: the effects of Helicobacter pylori on cell cycle control.- 22 Role of interleukin-1 beta and other potential genetic markers as indicators of gastric cancer risk.- 23 Results of intervention trials in Helicobacter pylori-infected populations.- 24 Which lessons can be drawn from the study of Helicobacter pylori related MALT lymphoma?.- Section V: Helicobacter pylori and Clinical Issues.- 25 Helicobacter pylori eradication leads to gastro-oesophageal reflux disease.- 26 Helicobacter pylori eradication does not lead to gastro-oesophageal reflux disease.- 27 Helicobacter pylori eradication in non-ulcer dyspepsia: the case for.- 28 Helicobacter pylori eradication does not benefit non-ulcer dyspepsia.- 29 Helicobacter pylori and dyspepsia strategies - debate: Yes - A test-and-treat strategy is a viable option in primary care.- 30 A 'test-and-treat' strategy is obsolete in primary care.- 31 Helicobacter pylori should be eradicated in patients receiving long-term acid suppression.- 32 Helicobacter pylori eradication is not necessary before longterm proton pump inhibitor treatment.- 33 Helicobacter pylori and non-steroidal anti-inflammatory drugs: the debate is over.- Section VI: Ongoing Clinical Issues with Helicobacter pylori Infection.- 34 What are the global response rates to Helicobacter pylori eradication therapy?.- 35 What is the Helicobacter pylori global reinfection rate?.- 36 Is it time for quadruple therapy to be first line?.- 37 Eradication therapy should be different for dyspeptic patients compared with ulcer patients.- 38 Helicobacter pylori resistance to antibiotics: prevalence, mechanism, detection. What's new?.- 39 Antibiotic sensitivities of Helicobacter pylori vary at different gastric mucosal sites.- 40 Can the response to eradication therapy in Helicobacter pylori infection be predicted?.- 41 What constitutes failure of H. pylori eradication therapy?.- 42 How can the current strategies for eradication therapy be improved?.- 43 Novel targets for Helicobacter pylori eradication.- 44 Helicobacter pylori managemen